Back to search results

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Anaplastic Astrocytoma · Infant Type Hemispheric Glioma · Glioblastoma · Glioblastoma Multiforme · WHO Grade III Glioma · WHO Grade IV Glioma · Diffuse Midline Glioma, H3K27-altered

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Children's Hospital Colorado, Aurora, Colorado, United States

    Contact: Study coordinator (Holly Lindsay, MD) · holly.lindsay@childrenscolorado.org

  • Children's National Medical Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Eugene Hwang) · ehwang@childrensnational.org

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

    Contact: Study coordinator (Ashley Plant, MD) · Aplant@luriechildrens.org

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Susan Chi) · Susan_chi@dfci.harvard.edu

  • Duke University Health System, Durham, North Carolina, United States

    Contact: Study coordinator (David Ashley, MD) · david.ashley@duke.edu

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Peter de Blank, MD) · Peter.deBlank@cchmc.org

  • Nationwide Children's Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Maryam Fouladi, MD, MSc) · Maryam.fouladi@nationwidechildrens.org

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Michael J Fisher, MD) · fisherm@email.chop.edu

  • Texas Children's Hospital, Houston, Texas, United States

    Contact: Study coordinator (Patricia Baxter, MD) · pabaxter@txch.org

  • Seattle Children's Hospital, Seattle, Washington, United States

    Contact: Study coordinator (Erin Crotty, MD) · erin.crotty@seattlechildrens.org

  • Sydney Children's Hospital, Randwick, New South Wales, Australia

    Contact: Study coordinator (David Ziegler, MD) · d.ziegler@unsw.edu.au

  • Queensland Children's Hospital, South Brisbane, Queensland, Australia

    Contact: Study coordinator (Tim Hassall, MD) · tim.hassall@health.qld.gov.au

  • Perth Children's Hospital, Perth, Western Australia, Australia

    Contact: Study coordinator (Nicholas G Gottardo, MBChB) · nick.gottardo@health.wa.gov.au

  • The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada

    Contact: Study coordinator (Eric Bouffet) · eric.bouffet@sickkids.ca

  • Montreal Children's Hospital, Montreal, Quebec, Canada

    Contact: Study coordinator (Genevieve Legault, MD) · Genevieve.legault4@mcgill.ca

  • Hopp Children's Cancer Center at NCT Heidelberg (KiTZ), Heidelberg, Baden-Wurttemberg, Germany

    Contact: Study coordinator (Olaf Witt, MD) · o.witt@kitz-heidelberg.de

  • Princess Máxima Center, Utrecht, Netherlands

    Contact: Study coordinator (Jasper van der Lugt) · J.vanderLugt@prinsesmaximacentrum.nl

  • Starship Children's Hospital, Auckland, Grafton, New Zealand

    Contact: Study coordinator (Sarah Hunter, MB ChB) · SHunter@adhb.govt.nz · +64 9 367 0000
Study leads

  • Hamza Gorsi, MD

    Study Chair

    Children's Hospital of Michigan

  • Susan Chi, MD

    Study Chair

    Dana-Farber Cancer Institute

  • Maryam Fouladi, MD

    Principal Investigator

    Nationwide Children's Hospital

View source on ClinicalTrials.gov(opens in a new tab)